GHRL and obesity due to melanocortin 4 receptor deficiency: Although the relative contribution of each of these actions to the preservation of vascular function cannot be directly extrapolated from the current findings, the results of this study provide a rationale for the therapeutic use of unacylated ghrelin in the treatment of vascular dysfunction and cardiovascular disease in conditions associated with altered peptide levels, such as obesity and insulin resistance.